KRYS
Krystal Biotech, Inc.Healthcare · $9.9B market cap
Verdict
Share price
$322.28
close of Oct 3, 2026
Fair value
$215.71
Sticker Price
Payback Price
$86.29
buy price
KRYS is Overpriced: at $322.28 it trades 49% above its fair value of $215.71. Its buy price (Payback Price) is $86.29, 73% below today's price. Business quality is strong: 4 of 5 key numbers clear the 10% bar.
How we valued it
Free Cash Flow. There are fewer than 4 years of sales history, too few to confirm a fast-growth phase, so we value it on its free cash flow instead of an earnings forecast.
Business quality
4 of 5 clear the 10% bar. What are the Big Five?
Follow KRYS
Get notified when it reaches its buy price of $86.29. Free.
Create a free accountSuperinvestors
1 of the investors we track holds KRYS. Who we track
Insider activity
Since Sep 4, 2026: no open-market purchases and 26 sales worth $18.0M. Why purchases matter
Sales
Krishnan Krish S
President and CEO · 2026-09-04
Sold
$148K
Krishnan Krish S
President and CEO · 2026-09-04
Sold
$310K
Krishnan Krish S
President and CEO · 2026-09-04
Sold
$495K
Krishnan Krish S
President and CEO · 2026-09-04
Sold
$208K
Krishnan Krish S
President and CEO · 2026-09-04
Sold
$729K
Show all 26 salesShow fewer
Krishnan Krish S
President and CEO · 2026-09-04
Sold
$439K
Krishnan Krish S
President and CEO · 2026-09-04
Sold
$817K
Krishnan Krish S
President and CEO · 2026-09-04
Sold
$1.2M
Krishnan Krish S
President and CEO · 2026-09-04
Sold
$1.1M
Krishnan Krish S
President and CEO · 2026-09-04
Sold
$1.4M
Krishnan Krish S
President and CEO · 2026-09-04
Sold
$1.2M
Krishnan Krish S
President and CEO · 2026-09-04
Sold
$721K
Krishnan Krish S
President and CEO · 2026-09-04
Sold
$184K
Krishnan Suma
President, R&D · 2026-09-04
Sold
$146K
Krishnan Suma
President, R&D · 2026-09-04
Sold
$302K
Krishnan Suma
President, R&D · 2026-09-04
Sold
$484K
Krishnan Suma
President, R&D · 2026-09-04
Sold
$205K
Krishnan Suma
President, R&D · 2026-09-04
Sold
$722K
Krishnan Suma
President, R&D · 2026-09-04
Sold
$449K
Krishnan Suma
President, R&D · 2026-09-04
Sold
$836K
Krishnan Suma
President, R&D · 2026-09-04
Sold
$1.2M
Krishnan Suma
President, R&D · 2026-09-04
Sold
$1.1M
Krishnan Suma
President, R&D · 2026-09-04
Sold
$1.4M
Krishnan Suma
President, R&D · 2026-09-04
Sold
$1.2M
Krishnan Suma
President, R&D · 2026-09-04
Sold
$713K
Krishnan Suma
President, R&D · 2026-09-04
Sold
$184K
About Krystal Biotech, Inc.
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works